Keenova Therapeutics to Report First Quarter 2026 Financial Results on May 12, 2026

Keenova Therapeutics (NASDAQ:MNK) will report its first quarter 2026 financial results on May 12, 2026 before market open and will host a conference call the same day.

Rhea-AI Summary

Keenova Therapeutics (NASDAQ:MNK) will report its first quarter 2026 financial results on May 12, 2026 before market open and will host a conference call the same day.

The live call is scheduled for 8:00 a.m. ET, with an audio webcast accessible via the Investor Relations site and a replay available after the event.

Key Figures

Earnings date: May 12, 2026 Price change 24h: 1.25% 52-week high: 18.1 +4 more

Earnings date

May 12, 2026

First quarter 2026 financial results report date

Price change 24h

1.25%

Pre-announcement daily move

52-week high

18.1

Pre-announcement 52-week high level

52-week low

0.026

Pre-announcement 52-week low level

20-day average volume

126,789 shares

Recent average trading volume before this news

200-day moving average

3.59

Long-term trend reference before Q1 2026 earnings date news

Conference call time

8:00 a.m. ET

Scheduled time for Q1 2026 results call on May 12, 2026

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, April 30, 2026 /PRNewswire/ -- Keenova Therapeutics plc, a leading developer and manufacturer of branded therapeutics, announced today that it will report its first quarter 2026 financial results on Tuesday, May 12, 2026, before market open. The Company will host a conference call on the same day at 8:00 a.m. ET.

The audio webcast may be accessed through the Investor Relations section of the Company's website at investor.keenova.com under Events & Presentations or through this link. To access the call through a conference line, participants can register here to receive a dial-in number and personalized PIN to participate in the call. Participants are advised to join 10 minutes prior to the scheduled start time. A replay of the webcast will be available following the event.

About Keenova

Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives.

Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.

Headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. To learn more, please visit www.keenova.com.

Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Contacts

Investors
investor.relations@keenova.com

Media
media.relations@keenova.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/keenova-therapeutics-to-report-first-quarter-2026-financial-results-on-may-12-2026-302758692.html

SOURCE Keenova Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Keenova Therapeutics (MNK) release Q1 2026 results and how can investors listen?

Keenova will release Q1 2026 results on May 12, 2026 before market open. According to Keenova Therapeutics, the company will host an 8:00 a.m. ET conference call and an audio webcast via the Investor Relations site, with a replay available after the event.

What time is Keenova Therapeutics (MNK) conference call for Q1 2026 and when should participants join?

The conference call is scheduled for 8:00 a.m. ET on May 12, 2026 and participants should join 10 minutes early. According to Keenova Therapeutics, a dial-in and personalized PIN are provided after registration.

Where can I find the Keenova Therapeutics (MNK) webcast for the Q1 2026 results?

The audio webcast will be available on the company Investor Relations website under Events & Presentations. According to Keenova Therapeutics, investors can access the live stream at investor.keenova.com or use the provided conference registration link.

Will there be a replay of Keenova Therapeutics (MNK) Q1 2026 earnings webcast?

Yes, a replay of the webcast will be available after the event. According to Keenova Therapeutics, the audio replay will remain accessible via the Investor Relations site following the live conference call.

How do I register to join Keenova Therapeutics (MNK) Q1 2026 earnings call by phone?

Register through the provided conference registration link to receive a dial-in number and personalized PIN. According to Keenova Therapeutics, registrants will get call access details to join the May 12, 2026 8:00 a.m. ET call.